, the Fremont, Calif.- based biopharmaceutical company, said that Swiss
will discontinue its agreement with PDL to jointly develop and commercialize daclizumab for organ transplant patients on longer-term maintenance therapy.
The co-development agreement between PDL and Roche will formally terminate in May 2007.
Roche made this decision subsequent to a periodic internal review of its development programs.
This decision follows another decision by Roche earlier this year to discontinue its involvement in the co-development of daclizumab for the treatment of asthma.
As a result, PDL will hold exclusive development and commercial rights to daclizumab for transplant maintenance.
This story was created through a joint venture between TheStreet.com and IRIS.